Robert W. Baird Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM - Free Report) had its price objective lowered by Robert W. Baird from $115.00 to $105.00 in a research note published on Friday,Benzinga reports. The brokerage currently has an outperform rating on the medical device company's stock.

DXCM has been the topic of a number of other reports. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Canaccord Genuity Group lifted their target price on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $98.11.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $1.35 during mid-day trading on Friday, hitting $80.27. The company had a trading volume of 5,371,321 shares, compared to its average volume of 4,270,825. The stock's 50-day moving average price is $71.46 and its 200-day moving average price is $76.87. The company has a market capitalization of $31.47 billion, a price-to-earnings ratio of 56.13, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom has a 1 year low of $57.52 and a 1 year high of $132.26. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 earnings per share. On average, sell-side analysts forecast that DexCom will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 over the last three months. 0.32% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

A number of institutional investors have recently made changes to their positions in DXCM. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $3,334,000. Congress Asset Management Co. boosted its position in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after acquiring an additional 222,548 shares during the last quarter. First Hawaiian Bank boosted its stake in shares of DexCom by 556.1% in the 4th quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after buying an additional 19,629 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of DexCom during the 4th quarter worth approximately $5,812,000. Institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.